

This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

## Patient Group Direction (PGD)

For the administration or supply of

**Ibuprofen tablets 200mg, 400mg, oral suspension 100mg/5ml**

By registered health care professionals for

**Pyrexia with discomfort**

**Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice**

**PGD NUMBER - 103**

### 1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021

## 2. Medicines practice guideline 2: *Patient group directions*

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care [PGD website FAQs](#)

## 3. PGD development

Refer to [the NICE PGD competency framework for people developing PGDs](#)

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

## 4. PGD authorisation

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

## 5. PGD adoption by the provider

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job title and organisation	Signature	Date	Applicable or not applicable to area

## 6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the [NICE PGD competency framework for health professionals using PGDs](#)

	Requirements of registered Healthcare professionals working under the PGD
<b>Qualifications and professional registration</b>	<ul style="list-style-type: none"> <li>Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy</li> <li>Pharmacists must be practising in Manx Care authorised premises i.e. contracted pharmacy premises</li> </ul>
<b>Initial training</b>	<ul style="list-style-type: none"> <li>Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria</li> <li>Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD</li> <li>Local training in the use of PGDs</li> </ul>
<b>Competency assessment</b>	Staff will be assessed on their knowledge of drugs and clinical assessment as part the competency framework for registered health professionals using PGDs
<b>Ongoing training and competency</b>	The registered health care professionals should make sure they are aware of any changes to the recommendations for this medication; it is the responsibility of the registered health care professionals to keep up to date with continuing professional development. PGD updates will be held every two years

## 7. Clinical Conditions

<b>Clinical condition or situation to which this PGD applies</b>	Pyrexia with discomfort
<b>Inclusion criteria</b>	<ul style="list-style-type: none"> <li>• Patient experiencing Pyrexia with discomfort</li> <li>• Patients over the age of 3 months of age</li> <li>• Body weight over 5kg in weight</li> </ul>
<b>Exclusion criteria</b>	<ul style="list-style-type: none"> <li>• not licenced for children under 3 months of age or body weight under 5kg</li> <li>• varicella infection</li> <li>• patient suffering from asthma</li> <li>• hypersensitivity reaction to NSAIDs</li> <li>• patients in liver, kidney or heart failure</li> <li>• allergic to aspirin</li> <li>• active or history of recurrent peptic ulcer/haemorrhage</li> <li>• history of gastrointestinal bleeding or perforation, related to previous NSAID therapy</li> <li>• gastrointestinal ulceration</li> <li>• pregnancy</li> </ul>
<b>Cautions (including any relevant action to be taken)</b>	<ul style="list-style-type: none"> <li>• Allergic disorders (in adults)</li> <li>• Cardiac impairment (NSAIDs may impair renal function)</li> <li>• Cerebrovascular disease</li> <li>• Coagulation defects</li> <li>• Connective-tissue disorders</li> <li>• Crohn's disease (may be exacerbated)</li> <li>• Elderly (risk of serious side-effects and fatalities) (in adults)</li> <li>• Heart failure</li> <li>• Ischaemic heart disease</li> <li>• Peripheral arterial disease</li> <li>• Risk factors for cardiovascular events</li> <li>• Ulcerative colitis (may be exacerbated)</li> <li>• Uncontrolled hypertension</li> </ul>
<b>Arrangements for referral for medical advice</b>	Patient should be referred to a more experienced clinical practitioner for further assessment
<b>Action to be taken if patient excluded</b>	Patient should be referred to a more experienced clinical practitioner for further assessment
<b>Action to be taken if patient declines treatment</b>	<ul style="list-style-type: none"> <li>• A verbal explanation should be given to the patient on: the need for the medication and any possible effects or potential risks which may occur as a result of refusing treatment</li> <li>• This information must be documented in the patients' health records</li> <li>• Any patient who declines care must have demonstrated capacity to do so</li> <li>• Where appropriate care should be escalated</li> </ul>

## 8. Details of the medicine

<b>Name, form and strength of medicine</b>	<b>Ibuprofen</b> <ul style="list-style-type: none"> <li>• Tablets 200mg/400mg</li> <li>• Oral suspension 100mg/5ml</li> </ul>
<b>Legal category</b>	General Sales List (GSL) or Pharmacy (P) depending on preparation
<b>Indicate any <u>off-label use</u> (if relevant)</b>	None
<b>Route/method of administration</b>	Oral
<b>Dose and frequency</b>	<b>Pyrexia with discomfort</b> <b>By mouth:</b> <ul style="list-style-type: none"> <li>• <b>Child 3–5 months:</b> 50 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day</li> <li>• <b>Child 6–11 months:</b> 50 mg 3–4 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day</li> <li>• <b>Child 1–3 years:</b> 100 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day</li> <li>• <b>Child 4–6 years:</b> 150 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day</li> <li>• <b>Child 7–9 years:</b> 200 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day; maximum 2.4 g per day</li> <li>• <b>Child 10–11 years:</b> 300 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day; maximum 2.4 g per day</li> <li>• <b>Child from 12 years to Adult:</b> Initially 300–400 mg 3–4 times a day; increased if necessary up to 600 mg 4 times a day; maintenance 200–400 mg 3 times a day, may be adequate</li> </ul>
<b>Quantity to be administered and/or supplied</b>	<b>Administration:</b> As per dose , 3 to 4 times daily maximum  <b>Supply:</b> <ul style="list-style-type: none"> <li>• <b>Tablets:</b> One original pack of either 200mg or 400mg tablets (maximum 24 tablets)</li> <li>• <b>Oral solution:</b> One 100ml bottle</li> </ul>
<b>Maximum or minimum treatment period</b>	Maximum of 48 hours treatment
<b>Storage</b>	Room temperature

<b>Adverse effects</b>	<ul style="list-style-type: none"> <li>• acute kidney injury</li> <li>• agranulocytosis</li> <li>• anaemia</li> <li>• constipation</li> <li>• diarrhoea</li> <li>• gastrointestinal disorders</li> <li>• haemorrhage</li> <li>• leucopenia</li> <li>• headache severe cutaneous adverse reactions (SCARs)</li> <li>• meningitis aseptic (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)</li> <li>• liver disorder</li> <li>• oedema</li> <li>• oral ulceration</li> <li>• pancytopenia</li> <li>• renal papillary necrosis</li> <li>• shock</li> <li>• thrombocytopenia</li> <li>• vomiting</li> </ul>
<b>Records to be kept</b>	The administration of any medication given under a PGD must be recorded within the patient's medical records

## 9. Patient information

<b>Verbal/Written information to be given to patient or carer</b>	<ul style="list-style-type: none"> <li>• Verbal information must be given to patients and or carers for all medication being administered under a PGD</li> <li>• Where medication is being supplied under a PGD, written patient information leaflet must also be supplied</li> <li>• A patient information leaflet is available on request</li> </ul>
<b>Follow-up advice to be given to patient or carer</b>	If symptoms do not improve or worsen or you become unwell, seek medical advice immediately

## 10. Appendix A

<b>References</b>
<ol style="list-style-type: none"> <li>1. British National Formulary (BNF) available online: <a href="https://bnf.nice.org.uk">https://bnf.nice.org.uk</a></li> <li>2. Nursing and Midwifery (2018) "The code" available online: <a href="https://www.nmc.org.uk">https://www.nmc.org.uk</a></li> <li>3. Current Health Care Professions Council standards of practice</li> <li>4. General Pharmaceutical Council standards</li> <li>5. The General Optical Council</li> <li>6. Electronic medicines compendium available online: <a href="https://www.medicines.org.uk">https://www.medicines.org.uk</a></li> </ol>

## 11. Appendix B

<b>Health professionals agreed to practice</b>
<ul style="list-style-type: none"> <li>• Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor</li> <li>• A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves</li> </ul>